Pharmaceutical companies GlaxoSmithKline and Sanofi entered into an agreement on joint development of a vaccine for the prevention COVID-19, according to PharmaTimes. Under the agreement, Sanofi will provide to surface antigen s-protein of coronaviruses, and GlaxoSmithKline – your experience in the development of adjuvants.
In the development of new vaccines will involve recombinant DNA technology, already tested in the production of flu vaccines. Add company GlaxoSmithKline adjuvant will enhance the immune response to the vaccine.
Earlier, Sanofi announced that studies of recombinant vaccine COVID-19 carried out with the support of the office of advanced biomedical research and development USA (BARDA).